Although the first PIM inhibitor SGI-1776 is withdrawn from clinical trials due to cardiac toxicity [91], it has helped in accelerating the discovery of novel PIM inhibitors in recent years, and several other candidates are currently tested in clinical trials for the treatment of cancers, including GBM [92]. Here, PIM1 is linked to glioblastoma.